Browsing Tag

Biosplice Therapeutics

Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a…

Jason Junior Nov 11, 2022

SAN DIEGO, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, announced…

Health

First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology

Jason Junior Nov 17, 2021

SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, announced the dosing of the…

Health

Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3…

Jason Junior Sep 15, 2021

SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and…

Health

Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee…

Jason Junior Jul 22, 2021

Lorecivivint post-hoc analysis reveals significantly increased likelihood of symptom improvements for knee osteoarthritis compared to placebo SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a…